Liver mass screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Liver mass}}
{{Liver mass}}
{{CMG}} {{AE}}{{MV}}
{{CMG}}; {{AE}}{{MV}}


==Overview==
==Overview==
Line 26: Line 26:
** [[Primary biliary cirrhosis]]
** [[Primary biliary cirrhosis]]
** [[Alpha-1 antitrypsin deficiency]]
** [[Alpha-1 antitrypsin deficiency]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
Line 34: Line 34:
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Primary care]]
[[Category:Surgery]]

Latest revision as of 22:32, 29 July 2020

Liver Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Evaluation of Liver Mass

Staging

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Liver mass screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liver mass screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liver mass screening

CDC on Liver mass screening

Liver mass screening in the news

Blogs on Liver mass screening

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Liver mass screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for benign liver mass. However, routine screening is recommended for individuals with chronic hepatitis B virus infection or cirrhosis from any cause who are at risk for development of HCC by ultrasound every 6 months.

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for benign liver mass. However, routine screening is recommended for individuals with chronic hepatitis B virus infection or cirrhosis from any cause who are at risk for development of HCC by ultrasound every 6 months. [1]

Recommended High-Risk Population for Screening for Hepatocellular Carcinoma

References

  1. Recommendations. US preventive services task force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=liver+mass Accessed on March, 24th 2016